Now we are up big, with 1.22 high up 22%. That is 3 year new highs, near all time highs blue sky breakout of 1.29
This is an easy stock for people to relate to and understand. It can become a popular stock both with pros and public alike.
Imagine what happens when FDA approves it.
LexaGene’s MiQLab is designed for point-of-care use and for simultaneous screening of numerous respiratory pathogens, including COVID-19 strain identification. The system is open-access, which allows for new tests to be easily loaded onto the system. This is a unique feature that is not found in any other system designed for point-of-care use.
Dr. Jack Regan, LexaGene’s CEO and Founder states, “Just three weeks ago, we designed assays to detect the UK and SA variants to demonstrate proof-of-principle that these assays could be quickly ported onto the MiQLab. ”